SCHEMBL25075490

SCHEMBL25075490

CC(C)CC1CN(CC(=O)N2CCC(C(C)C)CC2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.41
LMNA P02545 2/20 0.41
RAB9A P51151 1/20 0.41
PKM P14618 1/20 0.37
BIRC2 Q13490 1/20 0.36
ALDH1A1 P00352 4/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 2/20 0.35
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CPN1 P15169 1/20 0.33
CPB2 Q96IY4 1/20 0.33
HSD11B1 P28845 1/20 0.33
POLB P06746 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25075104 0.92 BIRC2 (0.38) KDM4ELMNARAB9APKMBIRC2
SCHEMBL25075121 0.92 BIRC2 (0.38) KDM4ELMNARAB9APKMBIRC2
SCHEMBL25075133 0.92 BIRC2 (0.38) KDM4ELMNARAB9APKMBIRC2
SCHEMBL25075446 0.88 PKM (0.40) KDM4ELMNARAB9APKMALDH1A1
SCHEMBL26497686 0.88 LMNA (0.40) KDM4ELMNARAB9APKMBIRC2
SCHEMBL25075102 0.86 LMNA (0.43) KDM4ELMNARAB9APKMBIRC2
SCHEMBL26494190 0.86 NPC1 (0.41) ALDH1A1NPC1HSD11B1POLBNPSR1
SCHEMBL26494191 0.83 NPC1 (0.45) ALDH1A1NPC1HSD11B1POLBL3MBTL1
SCHEMBL24330246 0.82 GAA (0.47) KDM4ELMNARAB9APKMBIRC2
SCHEMBL25075124 0.81 BIRC2 (0.43) KDM4ELMNARAB9APKMBIRC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN KDM4E 551/4885LMNA 3719/4885RAB9A 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.